Cancer cell migration blocked by 90% in pancreatic tumors, researchers discover

A novel strategy emerges for tackling pancreatic cancer

According to НВ — Техно: A team of international scientists from Florida A&M University's College of Pharmacy and Pharmaceutical Sciences has introduced a promising new method for treating pancreatic cancer driven by KRAS gene mutations-the root cause of most pancreatic tumors. On July 2 at 5:30 PM, their findings were released, detailing experiments with compounds called polyisoprenylated cysteinyl amide inhibitors (PCAIs), which showed encouraging outcomes.

What the study revealed

Published in the journal Oncotarget, the research highlights that a specific compound, NSL-YHJ-2-27, at low concentrations, halted over 90% of malignant cell movement. Tests were conducted on lab-grown pancreatic cancer cell cultures. PCAI compounds work by activating tumor-suppressing genes while deactivating those that promote tumor growth. This reduces the levels of proteins responsible for cell motility and breaks down actin filaments, which are crucial for cell movement.

The study also involved testing the compounds on three-dimensional (3D) miniature tumor models. The drug triggered a signaling overload and increased reactive oxygen species, ultimately leading to cellular self-destruction. It is important to note that this development is still in its early stages, having only been tested in lab settings on cell lines. Future steps include assessing the compounds' safety for healthy tissues and conducting animal trials.

The researchers believe this approach could extend beyond pancreatic cancer to treat colorectal and lung cancers as well. KRAS gene mutations are found in roughly 30% of all solid tumors, making this discovery highly relevant for a broad range of cancers.

This study holds significant potential for advancing new therapeutic strategies against cancer, especially given pancreatic cancer's high mortality rate and limited treatment options.

Further research, particularly clinical trials, will be essential to evaluate the safety and effectiveness of PCAI compounds in humans. If successful, these could set new standards for treating cancers caused by KRAS mutations. The development of drugs capable of targeting a wide array of cancers also opens up fresh possibilities for personalized medicine in oncology.

As researchers explore innovative cancer treatments, another groundbreaking approach involves utilizing engineered parasitic worms as living drug factories within the body. This method aims to deliver targeted therapies more effectively, potentially complementing the advancements made in pancreatic cancer treatment. Such developments highlight the ongoing efforts to combat various forms of cancer through novel strategies.